Disease · MONDO_0008315

prostate cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. prostate cancer. Diseases, record MONDO_0008315. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008315

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: prostate cancer; Open Targets
Open Targets ID: MONDO_0008315; Open Targets
Other names: cancer of prostate gland, malignant neoplasm of prostate, malignant neoplasm of prostate gland, malignant neoplasm of the prostate, malignant prostate gland neoplasm, malignant prostate neoplasm, malignant prostate tumor, malignant prostate tumour, malignant tumor of prostate, malignant tumor of the prostate, malignant tumour of prostate, malignant tumour of the prostate, prostate gland cancer; Open Targets
Disease Ontology: DOID:10283; Disease Ontology
MeSH: D011471; MeSH
NCI Thesaurus: C7378; NCI Thesaurus
Highest stage of its drugs: Approval, for 33 of its 757 drugs, from ClinicalTrials.gov, DailyMed, FDA, PMDA and TTD; Open Targets

Drugs757

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ENZALUTAMIDE	CHEMBL1082407	Small molecule	Approval	ClinicalTrials.gov, DailyMed, PMDA and TTD	258	255	255	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	ClinicalTrials.gov	197	197	195	Drugs and targets
ABIRATERONE ACETATE	CHEMBL271227	Small molecule	Approval	ClinicalTrials.gov, DailyMed, PMDA and TTD	193	188	188	Drugs and targets
BICALUTAMIDE	CHEMBL409	Small molecule	Approval	TTD	130	129	126	Drugs and targets
APALUTAMIDE	CHEMBL3183409	Small molecule	Approval	DailyMed and PMDA	111	108	108	Drugs and targets
DEGARELIX	CHEMBL415606	Protein	Approval	TTD	95	93	92	Drugs and targets
DAROLUTAMIDE	CHEMBL4297185	Small molecule	Approval	DailyMed, PMDA and TTD	89	86	86	Drugs and targets
ABIRATERONE	CHEMBL254328	Small molecule	Approval	TTD	86	85	85	Drugs and targets
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	CHEMBL4594406	Protein	Approval	FDA and TTD	82	78	19	Drugs and targets
LEUPROLIDE ACETATE	CHEMBL1200775	Protein	Approval	DailyMed, PMDA and TTD	79	76	75	Drugs and targets

1 to 10 of 757

See all 757 drugs

Targets537

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBB	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/347733	Drugs and targets
TUBB3	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10381	Drugs and targets
TUBB4A	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10382	Drugs and targets
TUBB4B	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10383	Drugs and targets
TUBB6	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/84617	Drugs and targets
TUBB8	Tubulin	23	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/347688	Drugs and targets
TUBA1A	Tubulin	22	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7846	Drugs and targets

1 to 10 of 537

See all 537 targets

Trials2,173

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 145 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02167893	Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"		11,288	2017-03-29	Prostate Cancer	LEUPROLIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT05520138	Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)		5,506	2024-09-27	Prostatic Neoplasms, Castration-Resistant	ABIRATERONE ACETATE, ENZALUTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00002651	SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer	Phase 3	3,040	2017-04-17	Prostate Cancer	BICALUTAMIDE, GOSERELIN ACETATE	Its record names the disease	ClinicalTrials.gov
NCT06072196	A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)		3,017	2025-12-31	Prostatic Neoplasms	ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05968599	A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer		2,731	2026-02-25	Prostatic Neoplasms, Castration-Resistant	ABIRATERONE ACETATE, ENZALUTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01081873	Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer		2,717	2012-03-26	Prostatic Neoplasm	LEUPROLIDE	Its record names the disease	ClinicalTrials.gov
NCT00626548	A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer	Phase 3	2,577	2012-06-01	Prostate Cancer	ZIBOTENTAN	Its record names the disease	ClinicalTrials.gov
NCT06151418	A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces		2,313	2025-06-04	Prostatic Neoplasms	ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01306890	A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer		1,976	2019-06-07	Advanced Prostate Cancer, Prostatic Neoplasms	SIPULEUCEL-T	Its record names the disease	ClinicalTrials.gov
NCT00744497	Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer	Phase 3	1,930	2014-02-06	Prostatic Neoplasms	DASATINIB ANHYDROUS, DOCETAXEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 2,173

See all 2,173 trials

Comparisons in its trials655

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Abiraterone vs Enzalutamide: deaths from any cause	2,523 of 2,911	2,176 of 2,595	5,506	NCT05520138	Trial comparisons
Abiraterone vs Enzalutamide: deaths from any cause	1,007 of 1,316	1,036 of 1,415	2,731	NCT05968599	Trial comparisons
Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): deaths from any cause	41 of 879	42 of 868	1,747	NCT00869206	Trial comparisons
Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): serious adverse events	96 of 879	103 of 868	1,747	NCT00869206	Trial comparisons
Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings	130 of 770	163 of 784	1,554	NCT01193244	Trial comparisons
Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: serious adverse events	321 of 770	380 of 784	1,554	NCT01193244	Trial comparisons
Dasatinib vs Placebo: serious adverse events	381 of 761	317 of 757	1,518	NCT00744497	Trial comparisons
Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: deaths from any cause	119 of 750	100 of 742	1,492	NCT00936390	Trial comparisons
TAS x 8 Weeks vs TAS x 28 Weeks: serious adverse events	121 of 747	109 of 735	1,482	NCT00005044	Trial comparisons
Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: Number of Participants With Acute Adverse Events	152 of 733	504 of 725	1,458	NCT00936390	Trial comparisons

1 to 10 of 655

See all 655 comparisons in its trials

Papers from its trials1,130

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40383193	RESULT	1	PubMed
40334149	RESULT	1	PubMed
39513948	RESULT	1	PubMed
39430616	RESULT	1	PubMed
39242323	RESULT	1	PubMed
39162634	RESULT	1	PubMed
39134652	RESULT	1	PubMed
39031642	RESULT	1	PubMed
38926066	RESULT	1	PubMed
38534939	RESULT	1	PubMed

1 to 10 of 1,130

See all 1,130 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008315

GET https://conductscience.org/api/diseases/v1/MONDO_0008315/drugs?page=2

API reference For AI assistants